🌿 Cellular Wharton’s Jelly Therapy

Advanced Signaling Cell Healing from Umbilical Cord Tissue

What Is Wharton’s Jelly?

Wharton’s Jelly is a gel-like substance found in the umbilical cord that surrounds the blood vessels. It is rich in mesenchymal Signaling cells (MSCs), growth factors, cytokines, and natural healing proteins. These components make Wharton’s Jelly an exceptional source for regenerative medicine¹.

Because it comes from donated umbilical cords after healthy births, it is young, potent, and ethically sourced with full FDA oversight of the tissue bank process.

Why It’s So Effective

Compared to signaling cells taken from an adult’s own body (like fat or bone marrow), Wharton’s Jelly-derived MSCs are more youthful, more active, and exist in higher numbers. This is especially important for older patients whose natural stem cell activity has declined over time².

Wharton’s Jelly cells can:

  • Reduce chronic inflammation
  • Stimulate tissue regeneration
  • Promote repair of cartilage, tendons, and bone
  • Help calm autoimmune responses

These cells do not carry a genetic identity, which makes them extremely tolerable and safe, with little to no risk of rejection or reaction³.

Conditions Treated with Cellular Wharton’s Jelly

At Johnson Medical Center, we use this therapy to support healing for:

  • Moderate to advanced arthritis
  • Chronic joint pain (knees, hips, shoulders, spine)
  • Degenerative disc disease
  • Tendon injuries
  • Sports injuries
  • Slow-healing tissue damage

We most often recommend this treatment for patients age 40 and older, whose stem cell vitality and population have naturally declined.

How the Procedure Works

  1. Evaluation: We assess your condition and determine whether Wharton’s Jelly signaling cells are a good fit for your needs.
  2. Injection: The treatment is performed in-office, with stem cells precisely injected into the problem area using ultrasound guidance.
  3. Recovery: There is little to no downtime. Over the next several weeks, the cells begin reducing inflammation and supporting healing.

Safety and Ethics

The umbilical cord tissue is collected from consented, full-term healthy births and processed in FDA-registered, cGMP-compliant laboratories. No embryonic material is used. The donors are screened and tested, and every step is in accordance with American Association of Tissue Banks (AATB) standards⁴.

A Powerful Option for Regeneration

For many of our patients Cellular Wharton’s Jelly provides a potent, non-surgical path to relief and recovery. It offers the best of regenerative medicine without the need to harvest tissue from your own body.

🔗 Sources
  1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926429/
  2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164302/
  3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497645/
  4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271833/

Regulatory Information

Johnson Medical Center is fully committed to complying with all Florida state and FDA regulations. Our MSC therapies are offered under approved protocols to ensure patient safety and regulatory adherence.

Before treatment, our patients receive detailed information about the investigational nature of MSC therapies, including potential risks and benefits, as required by Florida law. We are committed to ensuring you make an informed decision about your care.

Our umbilical cord-derived MSC therapies are processed in facilities that comply with FDA’s current Good Manufacturing Practices (cGMP) and Florida state regulations, ensuring the highest standards of safety and quality.

The mesenchymal signaling cell (MSC) therapies offered at Johnson Medical Center are investigational and not currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of arthritic joint conditions or soft tissue injuries. These therapies are provided under an FDA-approved clinical trial or expanded access program. Patients should be aware that experimental treatments carry risks, including infection or lack of efficacy, and should discuss these with their healthcare provider. To report any adverse events, please contact the FDA’s MedWatch program at www.fda.gov/medwatch or 1-800-FDA-0178.

In compliance with Florida law, Johnson Medical Center informs patients that our mesenchymal signaling cell (MSC) therapies are not approved by the FDA for the treatment of arthritic joint conditions or soft tissue injuries. Our clinic is registered with the Florida Department of Health, lab adheres to FDA manufacturing standards, and undergoes annual state inspections. During the informed consent process, we provide detailed information about the investigational nature of these therapies, including potential risks and benefits.